Country
Belgium
Galapagos NV has reported positive topline data from an early clinical trial of a small molecule antagonist of GPR84 in patients with idiopathic pulmonary fibrosis. The placebo-controlled study enrolled 68 patients but was not powered to show statistical significance.
Full text available to subscribers only. Click here for information on subscribing to MedNous.